Introduction {#sec1}
============

Esophageal carcinoma (EC) is one of the most serious malignant tumors of the digestive system. The morbidity rate of EC ranks eighth and the mortality rate ranks sixth among malignant tumors worldwide \[[@cit0001], [@cit0002]\]. Two histologic types are typical among EC patients: esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC). Patients in Western countries predominantly develop EAC, while Chinese patients typically develop ESCC. About 50% of ESCCs are formed in the middle esophagus \[[@cit0003]\]. Surgical removal is currently the most common treatment for ESCC, but the prognosis after a radical operation is less than ideal. According to recent studies, surgical treatment only gives ESCC patients at stages IIA--III a 5-year survival rate of 20--34% and fails to effectively eliminate distal metastasis and local tumor recurrence \[[@cit0004]\]. Currently, the TNM classification of malignant tumors serves as the primary basis for determining ESCC prognosis. The lack of objective quantitative indicators to accurately predict prognosis lends itself to opportunities for improvement \[[@cit0005]\].

Long noncoding RNAs (lncRNA) have emerged as influential factors in the occurrence and development of tumors. LncRNAs are more than 200 nucleotides in length and in most cases are produced by RNA polymerase II and undergo post-transcriptional modifications, such as capping and intron splicing. LncRNA genes usually contain few introns and have low levels of transcription, low conservation among different species, and in most cases have spatiotemporal expression specificity \[[@cit0006], [@cit0007]\]. Although this type of RNA does not have protein-encoding function, it can regulate gene expression at the chromosome, chromatin, transcriptional, and post-transcriptional levels and exerts significant regulatory effects through, inter alia, genomic imprinting, cell differentiation, immune reactions, tumor occurrence, and embryonic stem cell multi-potency. Recent studies have shown that multiple lncRNAs can produce small molecular peptides through transcription to become the driving force for the generation of new proteins \[[@cit0008]--[@cit0010]\]. In multiple large-scale screening studies, the expression of over 100 lncRNAs in ESCC tissues has been found to be altered. The abnormal expression of lncRNAs is mostly present during the evolution of highly differentiated intraepithelial neoplasia into invasive carcinoma, reflecting the important role of lncRNA in the development of ESCC \[[@cit0011]--[@cit0013]\].

Two genes known to encode lncRNAs are urothelial cancer associated 1 (*UCA1*) and metastasis associated lung adenocarcinoma transcript 1 (*MALAT1*). Li *et al.* reported that the relative level of UCA1 was significantly higher in ESCC tissues compared to the adjacent non-tumor tissue, and remarkably higher expression of UCA1 was found in esophageal cancer cell lines compared with the immortalized esophageal epithelial cell line NE1 \[[@cit0014]\], and it was found to be deregulated in cisplatin-resistant cells compared with their parent cells \[[@cit0015]\]. MALAT1 was over-expressed in 46.3% of ESCC tissues. The enhanced MALAT1 expression levels were positively correlated with clinical stages, primary tumor size, and lymph node metastasis, and inhibition of MALAT1 suppressed tumor proliferation *in vitro* and *in vivo*, as well as the migratory and invasive capacity \[[@cit0016]\]. Furthermore, silencing of MALAT1 could significantly suppress the proliferation of ESCC cells through the arrest of the G2/M cell cycle, which may be due to MALAT1-mediated up-regulation of p21 and p27 expression and the inhibition of B-MYB expression \[[@cit0017]\]. Recently, animal experiments showed that knockdown of MALAT1 decreased tumor formation and improved survival \[[@cit0018]\]. Here, we describe the relationship between the expression of *UCA1* and *MALAT1* lncRNAs in ESCC tissues and the associated prognosis.

Material and methods {#sec2}
====================

Tissues samples {#sec2.1}
---------------

The tumor tissues and para-carcinoma tissues were taken from 100 ESCC patients who were admitted to the First Hospital of Yulin City between January 2007 and January 2014 and treated as participants of this case-control prospective study.

The adjacent carcinoma tissues had been obtained at least 5 cm away from the tumor. Patients were diagnosed with ESCC based on a postoperative pathological examination. Clinical characteristics of participants are shown in [Table I](#t0001){ref-type="table"}. Patients were monitored after surgery by telephone follow-up or visits to the patient's home, and the total survival (OS) and disease free survival (DFS) status was observed, with OS representing the time from surgery to death or the last follow-up visit and DFS representing the time from the surgery to the local recurrence, distal metastasis, or the last follow-up visit. This study was approved by the Ethics Committee of the First Hospital of Yulin City, and informed consent was given by all participants.

###### 

Clinical characteristics of study participants

  Characteristics                          Number of cases   Percentage
  ---------------------------------------- ----------------- ------------
  Gender:                                                    
   Male                                    75                75.0
   Female                                  25                25.0
  Age \[years\]:                                             
   ≤ 60                                    68                68.0
   \> 60                                   32                32.0
  Histological grade:                                        
   1--2                                    41                41.0
   3--4                                    59                59.0
  TNM stage:                                                 
   I--II                                   73                73.0
   III                                     27                27.0
  Pathological type:                                         
   Ulcerative carcinoma                    65                65.0
   Others                                  35                35.0
  Adjuvant chemotherapy or radiotherapy:                     
   Yes                                     59                59.0
   No                                      41                41.0

Detection of lncRNAs {#sec2.2}
--------------------

Expression levels of *UCA1* and *MALAT1* lncRNAs were detected in the tumor tissues and para-carcinoma tissues as follows: total RNA was extracted by RNAiso Plus (code no. 9108Q; TaKaRa Biotechnology Limited Company, Dalian, China), the PrimeScript RT reagent kit (code no. RR037A, TaKaRa Bio.) was used to transcribe and synthesize cDNA, and real-time quantitative PCR (q-RT PCR) was used to quantify target lncRNA with 18S as the internal reference. The primer sequences are shown in [Table II](#t0002){ref-type="table"}. The total reaction volume was 10 μl, including of 5 μl of SYBR Green I Master Mix, 1 μl of RNAiso Plus, 0.6 μl of forward primers (10 μmol/l), 0.6 μl of reverse primers (10 μmol/l), 1 μl of cDNA, and 1.8 μl of dH~2~O deionized water. The reaction conditions were: pre-degeneration at 95ºC for 10 s, 95ºC for 5 s, 60ºC for 5 s, and 72ºC for 31 s, and amplification for 40 cycles. The differences between the target lncRNA cycle threshold values (*Ct* values) and 18S *Ct* value were determined (Δ*Ct*) and the 2^--ΔΔ^*^Ct^* method was used to determine the relative expression of target lncRNA. Compared to the mean expression levels in ESCC tissues, the patients were categorized as having high *UCA1* expression, low *UCA1* expression, high *MALAT1* expression, and low *MALAT1* expression.

###### 

Primer sequences of target lncRNA

  LncRNAs   Primer                         Sequence
  --------- ------------------------------ ------------------------------
  UCA1      Forward                        5′-CTCTCCATTGGGTTCACCATTC-3′
  Reverse   5′-GCGGCAGGTCTTAAGAGATGAG-3′   
  MALAT1    Forward                        5′-CAGTGGGGAACTCTGACTCG-3′
  Reverse   5′-GTGCCTGGTGCTCTCTTAC C-3′    
  18 S      Forward                        5′-CAGCCACCCGAGATTGAGCA-3′
  Reverse   5′-TAGTAGCGACGGGCGGTGTG-3′     

Statistical analysis {#sec2.3}
--------------------

Data were analyzed using SPSS 19.0 statistical software (IBM, Armonk, NY). Measurement data were expressed as mean ± standard deviation and an independent sample *t* test was used to compare groups. Kaplan-Meier survival analysis was used to compare OS and DFS and the log-rank test was used to determine statistical significance. The Cox risk model was used to analyze factors influencing OS and DFS. A *p* level \< 0.05 indicated statistical significance.

Results {#sec3}
=======

*UCA1* and *MALAT1* lncRNAs are higher in ESCC tissues than in para-carcinoma tissues {#sec3.1}
-------------------------------------------------------------------------------------

The relative expression levels of *UCA1* were 0.485 ±0.248 in ESCC tissues and 0.199 ±0.122 in adjacent carcinoma tissues, with a significant difference (*t* = 10.348, *p* \< 0.05). Similarly, the expression levels of MALAT1 were 3.842 ±0.415 in ESCC tissues and 1.451 ±0.136 in adjacent carcinoma tissues, with a significant difference (*t* = 54.750, *p* \< 0.05).

*UCA1* and *MALAT1* lncRNA expression is correlated with TNM staging in ESCC tissues {#sec3.2}
------------------------------------------------------------------------------------

Patients were categorized as having high *UCA1* expression (49 cases), low *UCA1* expression (51 cases), high *MALAT1* expression (50 cases), and low *MALAT1* expression (50 cases) compared to the mean expression levels in ESCC tissues. Clinical characteristics were compared between groups and the difference in TNM staging between the high *UCA1* expression group and the low *UCA1* expression group as well as between the high *MALAT1* expression group and the low *MALAT1* expression group was statistically significant (χ^2^ = 12.257, 26.839, *p* \< 0.05). The difference in other clinical characteristics was not found to be statistically significant ([Tables III](#t0003){ref-type="table"} and [IV](#t0004){ref-type="table"}).

###### 

*UCA1* lncRNA expression in ESCC tissues and clinical characteristics

  Characteristics         Number of cases   *UCA1* high expression(*N* = 49)   *UCA1* low expression(*N* = 51)   χ^2^     *P*-value
  ----------------------- ----------------- ---------------------------------- --------------------------------- -------- -----------
  Gender:                                                                                                                 
   Male                   75                35                                 40                                0.654    \> 0.05
   Female                 25                14                                 11                                         
  Age \[years\]:                                                                                                          
   \> 60                  68                31                                 37                                0.990    \> 0.05
   \< 60                  32                18                                 14                                         
  Histological grade:                                                                                                     
   1--2                   41                22                                 19                                0.603    \> 0.05
   3--4                   59                27                                 32                                         
  TNM stage:                                                                                                              
   I--II                  73                28                                 45                                12.257   \< 0.05
   III                    27                21                                 6                                          
  Pathological type:                                                                                                      
   Ulcerative carcinoma   65                33                                 32                                0.233    \> 0.05
   Others                 35                16                                 19                                         

###### 

*MALAT1* lncRNA expression in ESCC tissues and clinical characteristics

  Characteristics         Number of cases   *MALAT1* high expression(*N* = 50)   *MALAT1* low expression(*N* = 50)   χ^2^     *P*-value
  ----------------------- ----------------- ------------------------------------ ----------------------------------- -------- -----------
  Gender:                                                                                                                     
   Male                   75                39                                   36                                  0.480    \> 0.05
   Female                 25                11                                   14                                           
  Age \[years\]:                                                                                                              
   \> 60                  68                36                                   32                                  0.735    \> 0.05
   \< 60                  32                14                                   18                                           
  Histological grade:                                                                                                         
   1--2                   41                19                                   22                                  0.372    \> 0.05
   3--4                   59                31                                   28                                           
  TNM stage:                                                                                                                  
   I--II                  73                25                                   48                                  26.839   \< 0.05
   III                    27                25                                   2                                            
  Pathological type:                                                                                                          
   Ulcerative carcinoma   65                31                                   34                                  0.396    \> 0.05
   Others                 35                19                                   16                                           

*UCA1* and *MALAT1* lncRNA expression in ESCC tissues is predictive of patient survival {#sec3.3}
---------------------------------------------------------------------------------------

The OS and DFS of patients with high *UCA1* and *MALAT1* lncRNA expression in ESCC tissues were significantly lower than those of patients with low expression levels (χ^2^ = 4.880, 5.894, 8.635, 8.906, *p* \< 0.05). OS, DFS, and 95% confidence intervals (CI) are shown in [Tables V](#t0005){ref-type="table"}, [VI](#t0006){ref-type="table"} and [VII](#t0007){ref-type="table"}, and the Kaplan-Meier statistical significance analytic curves are shown in [Figure 1](#f0001){ref-type="fig"}.

###### 

OS and DFS of ESCC patients

  Survival        Estimate   Std. error   95% CI   
  --------------- ---------- ------------ -------- --------
  OS \[month\]    46.069     3.815        38.591   53.547
  DFS \[month\]   43.457     3.996        35.625   51.288

###### 

OS and DFS of patients with different *UCA1* lncRNA expression levels

  Groups                 Survival   Estimate   Std. Error   95% CI   
  ---------------------- ---------- ---------- ------------ -------- --------
  UCA1 high expression   OS         53.754     5.096        43.766   63.741
                         DFS        51.636     5.403        41.046   62.225
  UCA1 low expression    OS         37.538     5.365        27.023   48.052
                         DFS        31.855     4.891        22.269   41.442

###### 

OS and DFS of patients with different MALAT1 lncRNA expression levels

  Groups                   Survival   Estimate   Std. error   95% CI   
  ------------------------ ---------- ---------- ------------ -------- --------
  MALAT1 high expression   OS         57.089     5.136        47.022   67.156
                           DFS        54.440     5.540        43.582   65.299
  MALAT1 low expression    OS         32.999     4.760        23.670   42.329
                           DFS        27.819     4.289        19.413   36.225

![A -- Kaplan-Meier survival curve of OS of patients, B -- Kaplan-Meier survival curve of DFS of patients, C -- Kaplan-Meier survival curve of OS of patients with different *UCA1* lncRNA expression levels, D -- Kaplan-Meier survival curve of DFS of patients with different *UCA1* lncRNA expression levels, E -- Kaplan-Meier survival curve of OS of patients with different *MALAT1* lncRNA expression levels, F -- Kaplan-Meier survival curve of DFS of patients with different *MALAT1* lncRNA expression levels](AMS-14-31922-g001){#f0001}

Multiple factors influence the survival of ESCC patients {#sec3.4}
--------------------------------------------------------

Cox survival models revealed that OS and TNM staging (HR = 2.516) were significantly correlated (*p* \< 0.05) with *UCA1* lncRNA (HR = 1.638) and *MALAT1* LncRNA (HR = 1.553) in ESCC patients. In addition, DFS and TNM staging (HR = 2.881) were also correlated with *UCA1* lncRNA (HR = 1.662) and *MALAT1* lncRNA (HR = 1.713), as shown in [Tables VIII](#t0008){ref-type="table"} and [IX](#t0009){ref-type="table"}.

###### 

Multiple factors influence OS in ESCC patients

  Item                     β       χ^2^    HR      *p*-value
  ------------------------ ------- ------- ------- -----------
  TNM stage (stage III)    0.794   5.116   2.516   \< 0.05
  UCA1 high expression     0.436   6.025   1.638   \< 0.05
  MALAT1 high expression   0.237   4.915   1.553   \< 0.05

###### 

Multiple factors influence DFS in ESCC patients

  Item                     β       χ^2^    HR      *p*-value
  ------------------------ ------- ------- ------- -----------
  TNM stage (stage III)    0.662   4.628   2.881   \< 0.05
  UCA1 high expression     0.168   5.604   1.662   \< 0.05
  MALAT1 high expression   0.339   6.113   1.713   \< 0.05

Discussion {#sec4}
==========

In this study, *UCA1* and *MALAT1* lncRNA in ESCC tissues were found to have increased expression levels compared to adjacent carcinoma tissues and were significantly correlated with TNM staging. The results of this study indicate that the expression levels of these two lncRNAs are up-regulated in ESCC tissues and may play important roles in ESCC pathogenicity.

The OS and DFS of patients with high expression of *UCA1* and *MALAT1* lncRNAs in ESCC tissues were found to be significantly lower than those of patients with low expression levels, suggesting that the high expression of these two types of lncRNA played a role in determining OS and DFS. The degree to which *UCA1* and *MALAT1* lncRNAs changed in ESCC tissues was associated with the progression of the tumors and the patient's postoperative survival, suggesting that the expression of these lncRNAs might be used as auxiliary indicators to evaluate tumor progression and prognosis.

Relevant studies have revealed that UCA1 can promote the expression of *WNT6* and inhibit the expression of the p27 gene, and it can influence the stage of tumor cells through the PI3K/Akt signaling pathway to exert cancer-promoting effects on proliferation and apoptosis in a variety of cancer types \[[@cit0019], [@cit0020]\]. UCA1 can also regulate the expression of tumor drug resistance genes \[[@cit0021], [@cit0022]\], giving it the ability to enhance the proliferation, infiltration, and migration of ESCC cells and lower the sensitivity to anti-tumor drugs. Our results support previous studies suggesting that measuring *UCA1* expression could be a target for the treatment of ESCC and the evaluation of patient condition \[[@cit0023]\].

*MALAT1* can react with multiple proteins in the cell nucleus to influence gene regulation and cancer cell movement capability \[[@cit0024]\]. Previous studies have found that the inhibition of *MALAT1* can up-regulate the expression of caspase-8, caspase-3 and Bax, and down-regulate the expression of Bcl-2 and Bcl-xL, all of which were related to the development ESCC \[[@cit0025], [@cit0026]\]. The expression of *MALAT1* in ESCC tissues at the middle-advanced stage has been found to be higher than that at the early stage, and the amplitude of the up-regulation is associated with the progression of tumor TNM staging and lymph node metastasis, suggesting that the inhibition of *MALAT1* could stagnate the proliferation of ESCC tumor cells \[[@cit0027]\]. Therefore, abnormal expression of *MALAT1* in malignant tumor tissues and its involvement with cell cycle stage make it a potential target for the treatment of ESCC \[[@cit0028]\].

In conclusion, we found that the expression of *UCA1* and *MALAT1* lncRNAs is up-regulated in ESCC tissues and that their expression can impact the degree of tumor progression. This in turn impacts patients' postoperative survival time and can serve as an auxiliary index for predicting the prognosis of ESCC patients. Both lncRNAs are potential targets for ESCC treatments, and future studies will investigate the feasibility of interfering with their expression in a clinical setting.
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